Select country change
Shopping cart (0 , 0,00 ) Menu Search
Manufactured by BioVendor

GLP-1/Glucagon-Like Peptide Human

  • Regulatory status:RUO
  • Type:Synthetic protein
  • Other names:GLP-1
  • Species:Human
Please select your region to see available products and prices.
Cat. No. Size Price


RD172176100 0.1 mg
PubMed Product Details
Technical Data

Type

Synthetic protein

Description

Total 37 AA. MW: 4169.5 Da (Mass Spectral Analysis)

Amino Acid Sequence

His-Asp-Glu-Phe-Glu-Arg-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly

Purity

97.8% (RP-HPLC)

Formulation

Lyophilized

Reconstitution

Add deionized water to prepare a working stock solution of approximately 1.0 mg/mL and let the lyophilized pellet dissolve completely. Product is not sterile! Please filter the product by an appropriate sterile filter before using it in the cell culture.

Shipping

At ambient temperature. Upon receipt, store the product at the temperature recommended below.

Storage/Expiration

Store lyophilized peptide at –20°C. Lyophilized peptide remains stable until the expiry date when stored at –20°C. Reconstituted peptide can be stored at 4°C for a limited period of time.

Quality Control Test

RP-HPLC

Physical Appearance

White lyophilized (freeze-dried) powder.

Note

This product is intended for research use only.

Summary

Research topic

Diabetology - Other Relevant Products, Energy metabolism and body weight regulation

Summary

GLP-1 is a peptide hormone from the intestinal mucosa, which is produced from its precursor, proglucagon by post transnational processing. The mammalian proglucagon 1) is synthesized in the neuroendocrine L-cell of the intestine and the alpha-cells of the pancreas. It contains within its structure the sequences of glucagon and two glucagon-like peptides (GLP-1 and GLP-2) in tandem flanked at their amino and carboxyl termini by dibasic residues. GLP-1 is a 37 amino acids peptide and produced in the small intestine and in the pancreas in the human, in either C-terminal-amidated on glycine-extended form. GLP1 (7–36) amide and its receptor are present in several brain regions and may play a role in the physiological control of feeding4). Several reports have been presented as follows as to the biological activities of GLP-1. GLP-1 (7–37) and (7–36) amide is known as one of the most potent insulin secretagogues. GLP-1 (7–36) amide was supposed to improved glycemic control in patients with type 2 diabetes by increasing insulin secretion, by inhibiting glucagon secretion and by delaying gastric emptying rather than by altering extrapancreatic glucose metabolism. Intravenous GLP-1(7–37) and (7–36)amide could normalize fasting hyperglycaemia in type 2 diabetic patients. Hyperglycaemia during parenteral nutrition could be controlled by exogenous GLP-1, whereas the chronic therapy of type 2 diabetes required GLP-1 derivatives with longer duration of action. Recombinant GLP-1 (7–36) amide was recently shown to cause significant weight loss in type 2 diabetics when administered for 6 weeks as a continuous subcutaneous infusion, 5-day treatment of hereby obese human subjects with GLP-1 at high doses by prandial subcutaneous infusion promptly slowed gastric emptying as a probable mechanism of action of increased satiety, decreased hunger and reduced food intake with an ensuing weight loss. A G-protein-coupled receptor, GPR120, which is abundantly expressed in intestine, functions as a receptor for unsaturated long-chain FFAs (free fatty acids). The stimulation of GPR120 by FFAs promotes the secretion of GLP-1 in vitro (measured by YK160, Yanaihara Institute Inc) and in vivo, and increases circulation insulin, indicate that GPR120-mediated GLP-1 secretion induced by dietary FFAs is important in the treatment of diabetes. All these approaches have shown remarkable efficacy in both experimental and clinical studies. The GLP-1-based therapy of type 2 diabetes, therefore, represents a new and attractive alternative. Yanaihara Institute Inc. developed a quantitative EIA kit with high specificity and sensitivity (detection limit 0.206 ng/mL) for rat/mouse/human GLP-1 as a useful tool for these necessaries.

References to Summary

References to Glucagon-Like Peptide-1

  • Asarian L, Corp ES, Hrupka B, Geary N. Intracerebroventricular glucagon-like peptide-1 (7-36) amide inhibits sham feeding in rats without eliciting satiety. Physiol Behav. 1998 Jun 1;64 (3):367-72
  • Heinrich G, Gros P, Habener JF. Glucagon gene sequence. Four of six exons encode separate functional domains of rat pre-proglucagon. J Biol Chem. 1984 Nov 25;259 (22):14082-7
  • Hirasawa A, Tsumaya K, Awaji T, Katsuma S, Adachi T, Yamada M, Sugimoto Y, Miyazaki S, Tsujimoto G. Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nat Med. 2005 Jan;11 (1):90-4
  • Holst JJ. Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1. Diabetes Metab Res Rev. 2002 Nov-Dec;18 (6):430-41
  • Mojsov S, Kopczynski MG, Habener JF. Both amidated and nonamidated forms of glucagon-like peptide I are synthesized in the rat intestine and the pancreas. J Biol Chem. 1990 May 15;265 (14):8001-8
  • Naslund E, King N, Mansten S, Adner N, Holst JJ, Gutniak M, Hellstrom PM. Prandial subcutaneous injections of glucagon-like peptide-1 cause weight loss in obese human subjects. Br J Nutr. 2004 Mar;91 (3):439-46
  • Nauck MA, Walberg J, Vethacke A, El-Ouaghlidi A, Senkal M, Holst JJ, Gallwitz B, Schmidt WE, Schmiegel W. Blood glucose control in healthy subject and patients receiving intravenous glucose infusion or total parenteral nutrition using glucagon-like peptide 1. Regul Pept. 2004 Apr 15;118 (1-2):89-97
  • Nauck MA, Weber I, Bach I, Richter S, Orskov C, Holst JJ, Schmiegel W. Normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in type 2 diabetic patients. Diabet Med. 1998 Nov;15 (11):937-45
  • Orskov C, Rabenhoj L, Wettergren A, Kofod H, Holst JJ. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes. 1994 Apr;43 (4):535-9
  • Vella A, Shah P, Basu R, Basu A, Holst JJ, Rizza RA. Effect of glucagon-like peptide 1(7-36) amide on glucose effectiveness and insulin action in people with type 2 diabetes. Diabetes. 2000 Apr;49 (4):611-7
  • Yanaihara N. [Recent advances in gastrointestinal hormones]. Hum Cell. 1990 Mar;3 (1):1-8
Related Products Documents